37.62MMarket Cap-1363P/E (TTM)
0.1640High0.1500Low1.12MVolume0.1615Open0.1592Pre Close176.39KTurnover0.46%Turnover RatioLossP/E (Static)250.82MShares0.890052wk High2.59P/B36.67MFloat Cap0.110352wk Low--Dividend TTM244.45MShs Float3.9500Historical High--Div YieldTTM8.79%Amplitude0.1103Historical Low0.1580Avg Price1Lot Size
Matinas BioPharma Stock Forum
3 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data showing the use of L...
1 MINUTE AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxel
Results build on data from prior in vivo study of oral LNC-docetaxel showing reductions in tumor size comparable to IV-doce...
5 MINUTES AGO, 7:30 AM EST
VIA GLOBENEWSWIRE
No comment yet